Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: The DAVID study

European Heart Journal

Volumn 25, Issue 20, 2004, Pages 1845-1852

  Neri Serneri, Gian Gastone ^a   Coccheri, Sergio ^b   Marubini, Ettore ^c   Violi, Francesco ^d  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antiplatelet therapy; Aspirin; Diabetes; Peripheral arterial disease; Picotamide; Thromboxane synthase inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; PICOTAMIDE; THROMBOXANE A2 RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTERY DISEASE; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EYE TOXICITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MOTOR DYSFUNCTION; MULTICENTER STUDY; NEUROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; STATISTICAL SIGNIFICANCE; UROGENITAL TRACT DISEASE;

ADULT; AGED; ASPIRIN; DIABETIC ANGIOPATHIES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PHTHALIC ACIDS; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; SURVIVAL ANALYSIS; THROMBOXANE A2;

EID: 4944241267     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehj.2004.07.013     Document Type: Article

References (38)

1. M.L. Garcia, P.M. Mc Namara, and T. Gordon Morbidity and mortality in diabetes in the Framingham population: sixteen year follow-up study Diabetes 23 1974 105 111
2. G. Panzram Mortality and survival in type 2 diabetes (non insulin-dependent diabetes) Diabetologia 30 1987 123 131
3. Portuese E, Orchard T. Mortality in insulin-dependent diabetes. In: National Diabetes Data Group, editor. Diabetes in America. Bethesda (MD): National Institute of Health; 1995:233-55 (NIH Publication No. 95-1468)
4. Geiss LS, Herman WH, Smith PJ. Mortality in non-insulin-dependent diabetes. In: National Diabetes Data Group, editor. Diabetes in America. Bethesda (MD): National Institute of Health; 1995:233-55 (NIH Publication No. 95-1468)
5. Antiplatelet Trialist's Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106
6. Antithrombotic Trialist's Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 2002;324:71-86
7. M.R. Jackson, and G.P. Clagett Antithrombotic therapy in peripheral arterial occlusive disease Chest 114 1998 666S 682S
8. Food and Drug Administration. Internal analgesic, antipyretic, and antirheumatic drug products for OTC human use: final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid drug products. Fed Regist 1998;63:56802-19
9. P. Gresele, H. Deckmyn, and J. Arnout Characterization of N,N′-bis(3-pycolil)-4-methoxy-isophtalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonist in human platelets Thromb. Haemost. 61 1989 479 484
10. P.A. Modesti, A. Colella, and R. Abbate Competitive inhibition of platelet thromboxane A2 receptor binding by picotamide Eur. J. Pharmacol. 169 1989 85 93
11. I.S. Watts, K.A. Wharton, and B.P. White Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibitor alone and in combination: comparison of antiaggregatory efficacy in human platelets Br. J. Pharmacol. 121 1991 158 163
12. P.A. Modesti, I. Cecioni, and A. Colella Binding kinetics and antiplatelet activities of picotamide, a thromboxane A2 receptor antagonist Br. J. Pharmacol. 112 1994 81 86
13. P. Gresele, H. Deckmyn, and G.G. Nenci Thromboxane receptor antagonists and dual blockers in thrombotic disorders Trends Pharmacol. Sci. 121 1991 158 163
14. G. Davi, I. Catalano, and M. Averna Thromboxane biosynthesis and platelet function in type 2 diabetes mellitus NEJM 322 1990 1769 1774
15. F. Balsano, F. Violi and ADEP Group Effect of picotamide in the clinical progression of peripheral vascular disease. A double blind placebo-controlled study Circulation 87 1993 1563 1569
16. M. Milani, A. Longoni, and M. Maderna Effects of picotamide, an antiplatelet agent, on cardiovascular events in 438 claudicant patients with diabetes:a retrospective analysis of the ADEP study Br. J. Clin. Pharmacol. 42 1996 782 785
17. M. Muggeo, G. Verlato, and E. Bonora The Verona diabetes study: a population-based survey on known diabetes mellitus prevalence and 5-year all-cause mortality Diabetologia 38 1995 318 325
18. J.R. Gray A class of K-sample test for comparing the cumulative incidence of a competing risk Ann. Stat. 16 1998 1141 1154
19. E. Marubini, and M.G. Valsecchi Analysing survival data from clinical trials and observational studies 1995 Wiley New York
20. C. Cimminiello, and M. Milani Diabetes mellitus and peripheral vascular disease: is aspirin effective in preventing vascular event Diabetologia 39 1996 1402 1404
21. M. Sacco, F. Pellegrini, M.C. Roncaglioni on behalf of the PPP Collaborative Group Primary prevention of cardiovascular events with low-dose aspirin and Vitamin E in type 2 diabetic patients. Results of the Primary Prevention Project (PPP) trial Diabetes Care 26 2003 3264 3272
22. EDTRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early treatment diabetic retinopathy study report. JAMA 1992;268:1292-1300
23. Coffman JD. Intermittent claudication. Not so benign. Am Heart J 1986;112:131-3
24. A. Makin, S.H. Silverman, and G.Y.H. Lip Peripheral vascular disease and Virchow'S triad for thrombogenesis Q. J. Med. 95 2002 199 210
25. S. Coccheri, and G. Palareti The cardiovascular risk burden of intermittent claudication Eur. Heart J. Suppl. 4 Suppl. B 2002 B46 B49
26. J. Dormandy, and G. Murray The fate of the claudicant. A prospective study of 1968 claudicants Eur. J. Vasc. Surg. 5 1991 131 133
27. J.A. Colwell, S.F. Bingham, and C. Abraira Veterans Administration cooperative study group on antiplatelet agents in diabetic patients after amputation for gangrene. Effect of aspirin and dipyridamole on atherosclerotic vascular disease rates Diabetes Care 9 1986 140 148
28. J.G.F. Cleland Preventing atherosclerotic events with aspirin (editorial) Br. Med. J. 324 2002 103 105
29. J.S. Yudkin Which diabetic patients should be taking aspirin? Br. Med. J. 311 1995 641 642
30. A. Ceriello, and E. Motz Prevention of vascular events in diabetes mellitus Diabetologia 39 1996 1405 1406
31. J.D. Morrow, T.M. Harris, and L.J. Roberts Non cycloxygenase formation of a series of novel prostaglandins: analytical ramifications for measurement of eicosanoids Proc. Natl. Acad. Sci. USA 87 1990 9383 9387
32. C.J. Mullarkey, D. Edelstein, and M. Brownlee Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes Biochem. Biophys. Res. Commun. 173 1990 932 939
33. C. Watala, J. Golanski, J. Pluta, and M. Boncler Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicilic acid (aspirin): its relation to metabolic control Thromb. Res. 113 2004 101 113
34. G. Di Minno, and F. Violi Aspirin resistance and diabetic angiopathy: back to the future â€" editorial Thromb. Res. 113 2004 97 99
35. P.A. Insel Analgesic-antipyretic and antinflammatory agents A. Godman A. Gilman T.W. Rall A.S. Niec The pharmacological basis of therapeutics 9th ed. 1996 Pergamon Press New York 1712
36. M. Berrettini, M. De Cunto, and P. Parise In vitro and ex vivo effects of picotamide, a combined thromboxane A2-synthase inhibitor and receptor antagonist, on human platelets Eur. J. Clin. Pharmacol. 39 1990 495 500
37. P.A. Modesti, A. Colella, and I. Cecioni Capacity of picotamide to diffuse into the arterial wall and bind to receptor of vascular muscle cells Thromb. Haemost. 73 1995 1323
38. G.G. Neri Serneri, R. Abbate, and G.F. Gensini TxA2 production by human arteries and veins Prostaglandins 25 1983 753 765